- Market Capitalization, $K 33,869
- Shares Outstanding, K 5,132
- Annual Sales, $ 53,940 K
- Annual Income, $ -10,440 K
- 60-Month Beta 1.73
- Price/Sales 0.70
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
+3.39 (+80.91%)since 12/18/20
| || |
+2.97 (+64.43%)since 10/19/20
| || |
+0.53 (+7.52%)since 01/17/20
Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of...
The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.
Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President...
, /PRNewswire/ -- The report has been added to offering.
Bristol Myers' (BMY) phase III study on Opdivo in newly diagnosed glioblastoma failed to meet goals.
Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.
ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the treatment of C3 Glomerulopathy.
Veracyte (VCYT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.
Berkeley Lights (BLI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.